Place: Japan
| Development No. Generic name |
Therapeutic Category | Dosage form | Stage |
|---|---|---|---|
| Favipiravir | Anti-SFTS (serious fever with thrombocytopenia syndrome) virus agent | Oral |
Launch |
T-4288: Discontinued the development for ‘Otorhinolaryngology infectious disease’ and ‘Respiratory infectious disease’
(As of Nov. 2024)